1-20 of 350 Search Results for

pharmaceutical pricing

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
×Close Modal
Sort by
Journal Article
Journal of Health Politics, Policy and Law (1 June 2014) 39 (3): 691–705.
Published: 01 June 2014
... political and regulatory environment, this report explores pharmaceutical pricing options for Russia that balance greater access to medicines with achieving government plans of boosting local pharmaceutical production. To match innovative medicine prices with their health benefits, in the long run, we...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2003) 28 (1): 109–132.
Published: 01 February 2003
...Ramón Castellblanch A comparison of the Vermont and Maine cases of attempting to control pharmaceutical prices in the year 2000 shows that the Maine legislators were more successful in challenging pharmaceutical industry political power. This comparison shows that challenging the industry was...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2018) 43 (1): 5–18.
Published: 01 February 2018
... drugs will require close coordination among manufacturers, payers, and regulators. Copyright © 2018 by Duke University Press 2018 Medicaid best-price rule pharmaceutical pricing value-based payment outcome-based pricing Even in today's polarized political landscape, a consensus has emerged...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2009) 34 (6): 931–977.
Published: 01 December 2009
... health service to the present, as they have grappled with the overlapping challenges of pharmaceutical safety, efficacy, cost-effectiveness, pricing, promotion, and advertising. The article draws on the concepts of “corporate bias” and “regulatory capture” from political theory, and “counter-vailing...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 505–544.
Published: 01 June 2013
... . Calfee John E. 2002 . “Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs.” Journal of Public Policy and Marketing 21 , no. 2 : 174 – 93 . Capella Michael L. . 2009 . “Do Pharmaceutical Marketing Activities Raise Prices? Evidence from Five Major...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2012) 37 (5): 779–814.
Published: 01 October 2012
..., Australia, and the United Kingdom — specifically, why Canada alone failed to adopt nationwide, public pharmaceutical insurance. It demonstrates that the pace of change has significant implications for the scope of policy development. It provides new mechanisms to explain why incremental reforms stall based...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1992) 17 (4): 847–868.
Published: 01 August 1992
... registration procedure for new products, and price controls-being the most important from the standpoint of the European market. Major challenges confront the pharmaceuticals industry as the Commu- nity shifts toward an integrated single market. The multinational pharma- ceutical companies that...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2016) 41 (2): 157–179.
Published: 01 April 2016
... the quality of life (Lichtenberg 2005 ). However, the high price of patented pharmaceutical products results in higher costs to individuals in the form of higher insurance premiums, higher out-of-pocket payments for medications, and higher taxes to pay for government-funded care. Expensive new...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2006) 31 (5): 1015–1019.
Published: 01 October 2006
.... Christopher Scott Harrison. The Politics of the International Pricing of Prescription Drugs. Westport, CT: Praeger, 2004. 224 pp. $65.95 cloth. Richard Henry Parrish II. Defining Drugs: How Government Became the Arbiter of Pharmaceutical Fact. New Brunswick, NJ: Transaction Books, 2003. 163 pp. $29.95...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2013) 38 (4): 735–755.
Published: 01 August 2013
...Bhaven N. Sampat; Tahir Amin The 1995 Trade Related Intellectual Property Rights (TRIPS) agreement required developing countries to grant product patents in pharmaceuticals. Developing countries have since explored various measures to ameliorate potential negative effects of the new laws on public...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2011) 36 (4): 649–689.
Published: 01 August 2011
... when the effort does not face crippling political or legal opposition. As in other Medicare competitive-­pricing attempts, political pressure played a substantial role in the Part D bidding design. Partly because of the pharmaceutical industry’s lobbying efforts, Part D is restricted to pri...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2015) 40 (4): 711–744.
Published: 01 August 2015
...Robert Berenson Abstract Prices are the major driver of why the United States spends so much more on health care than other countries do. The pricing power that hospitals have garnered recently has resulted from consolidated delivery systems and concentrated markets, leading to enhanced negotiating...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2009) 34 (6): 979–1010.
Published: 01 December 2009
... both health care administrators and patients for high-quality, low-cost medicines and the objective of the innovator pharmaceutical industry to find and approve new drugs that are price protected and sell them in a way that maximizes revenues. Duke University Press 2009 Abbott, F. M. 2004 . The Doha...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2003) 28 (2-3): 473–508.
Published: 01 June 2003
... . Senate OK's Prescription Imports . Associated Press, 19 July. Castellblanch, Ramón. 2003 . Challenging Pharmaceutical Industry Political Power in Maine and Vermont. Journal of Health Politics, Policy and Law 28 : 109 -132. Cauchi, Richard. 2000 . Prescription Drug Discount, Rebate, Price...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2003) 28 (4): 615–658.
Published: 01 August 2003
... , ed. P. Davis. New York: Oxford University Press. Pharmaceutical Price Regulation Scheme (PPRS). 2000 . Fourth Report to Parliament . London: Government of the United Kingdom. Available on-line at www.doh.gov.uk/pprs.htm . Phillips, P. J. 1997 . Regulatory Approval Process. ASAIO Journal 43...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2016) 41 (3): 423–450.
Published: 01 June 2016
...) rights in these countries (Office of the United States Trade Representative 2015 ). Nongovernmental organizations (NGOs) such as Oxfam and Médecins Sans Frontières (Doctors without Borders) have long criticized this agreement for its intellectual property and pharmaceutical pricing provisions that are...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1998) 23 (2): 265–290.
Published: 01 April 1998
... a variety of published and unpublished sources, including interviews with public policy and pharmaceutical experts in each country. This article presents different approaches to encouraging the development of orphan drugs while ensuring access by regulating their prices. Additionally, the article...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1979) 4 (2): 155–175.
Published: 01 April 1979
... control prices of pharmaceuticals, prior to enactment of some form of national health insurance, if successful, will call forth pharmaceutical industry strategies which could negate program benefits. Copyright © 1979 by the Dept. of Health Administration, Duke University 1979 The authors wish to express...
Journal Article
Journal of Health Politics, Policy and Law (1 April 2008) 33 (2): 225–247.
Published: 01 April 2008
... for opportunity cost while conveying to the decision maker the price of maximizing health gains, subject to a budget or resource constraint. However, the underlying assumptions are implausible, particularly in the context of pharmaceutical care. Moreover, budget impact analysis is more useful to...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2018) 43 (5): 771–791.
Published: 01 October 2018
... Medicare paid $1,600. US spending on this procedure is much higher than abroad not because Americans consume higher hip replacements per capita—that is not the case—but solely due to the price of those hip replacements. A similar pattern applies to pharmaceuticals—Americans pay more for branded drugs than...